ABO Incompatible Kidney Transplant

ABO incompatible kidney transplants allow patients to receive kidneys from donors with different blood types, significantly expanding the donor pool. This procedure is particularly beneficial for patients with high antibody levels who have difficulty finding compatible donors. The success of ABO incompatible transplants relies on reducing the recipient’s blood group antibodies to prevent rejection of the transplanted kidney.

​

The process begins with plasmapheresis, a procedure that filters antibodies out of the recipient’s blood. This is often combined with immunosuppressive medications to further lower antibody levels. Intravenous immunoglobulin (IVIG) therapy may also be used to help modulate the immune system. Once the antibody levels are sufficiently reduced, the transplant can proceed.

​

Postoperative care for ABO incompatible transplants includes continued immunosuppressive therapy and regular monitoring to detect and manage any signs of rejection. Advances in this field have led to success rates comparable to those of ABO compatible transplants, making it a viable option for many patients.

​

However, ABO incompatible transplants do come with increased risks. The intensive pre-transplant conditioning can lead to complications such as infections and other immune-related issues. Additionally, there is a higher risk of acute rejection immediately after the transplant, necessitating vigilant postoperative care.

​

Despite these challenges, ABO incompatible kidney transplants have transformed the landscape of renal transplantation. They offer hope to many patients who might otherwise face long wait times for a compatible donor. The procedure requires a specialized approach and close coordination among a multidisciplinary team, but the potential to save lives and improve patient outcomes makes it a valuable option in modern transplant medicine.